BridgeMD
Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates
EU CTIS ID: 2026-526044-12-00
What this study is testing
To evaluate the efficacy and safety of pharmacological obesity treatment (BMI ≥ 30) in liver transplant candidates.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Liver transplant candidate undergoing pre-transplant evaluation (inpatient or outpatient) at the Department of Hepatogastroenterology, aged ≥18 years.
- BMI ≥ 30, or BMI ≥ 33 in case of significant fluid retention (edema of lower extremities, ascites, hydrothorax; for large ascites/hydrothorax, BMI will be evaluated after evacuation puncture).
- Clinically stable (patient is at home under outpatient follow-up or hospitalized on a standard ward without clinical or laboratory signs of significant deterioration or complications).
- Signed informed consent.
You likely can't join if
- Hepatic encephalopathy
- Refractory ascites/hydrothorax (≥2 evacuation procedures in the last 2 months).
- Combined liver-kidney transplantation.
- Pregnancy (pre-enrollment assessment includes a pregnancy test; women of childbearing potential must agree to use highly effective contraception — hormonal or barrier methods, or abstinence; highly effective methods are defined as those with failure rate <1% per year with correct and consistent use).
- History of acute or chronic pancreatitis.
- Polycystic liver disease
See the full eligibility criteria
- Liver transplant candidate undergoing pre-transplant evaluation (inpatient or outpatient) at the Department of Hepatogastroenterology, aged ≥18 years.
- BMI ≥ 30, or BMI ≥ 33 in case of significant fluid retention (edema of lower extremities, ascites, hydrothorax; for large ascites/hydrothorax, BMI will be evaluated after evacuation puncture).
- Clinically stable (patient is at home under outpatient follow-up or hospitalized on a standard ward without clinical or laboratory signs of significant deterioration or complications).
- Signed informed consent.
- Hepatic encephalopathy
- Refractory ascites/hydrothorax (≥2 evacuation procedures in the last 2 months).
- Combined liver-kidney transplantation.
- Pregnancy (pre-enrollment assessment includes a pregnancy test; women of childbearing potential must agree to use highly effective contraception — hormonal or barrier methods, or abstinence; highly effective methods are defined as those with failure rate <1% per year with correct and consistent use).
- History of acute or chronic pancreatitis.
- Polycystic liver disease
- Type 1 diabetes mellitus
- Liver malignancy outside Milan criteria (Milan-out, Klatskin tumor, colorectal carcinoma metastases, NET metastases).
- Unstable clinical condition or unplanned hospitalization due to significant deterioration or complication.
- Spontaneous weight loss (≥5% in the past 6 months, not due to diuretic or evacuation treatment).
- Sarcopenia according to pre-transplant CT.
- Inability to perform physical activity (walking 30 min/day).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.